Business Context and Reporting Period
This Form 8-K was filed by Greatbatch, Inc. on June 4, 2013, reporting events occurring on June 5, 2013. The filing details a strategic realignment of the Company's operating structure to unify sales, marketing, and operations across its Greatbatch Medical and Electrochem Solutions segments. This move marks a transition from a component developer to an organization capable of developing complete medical devices for OEM customers.
Key Financial Metrics
The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures. It focuses exclusively on estimated future costs and savings associated with the restructuring plan.
- Estimated Restructuring Charges: $4.2 million to $5.0 million (through end of 2014).
- Severance and Termination Benefits: $2.9 million to $3.2 million.
- Travel, Recruiting, and Relocation: $1.3 million to $1.8 million.
- Expected Annual Savings: $7.0 million to $7.7 million upon full implementation.
- Cash Impact: Charges are expected to consist primarily of cash expenditures.
Material Changes
The primary material change is the organizational restructuring announced on June 5, 2013. This involves unifying the sales and marketing and operations organizations of the two main business units. Additionally, the Company has appointed four new executive officers to lead the restructured organization:
- Mauricio Arellano: Appointed Executive Vice President for Global Operations (previously President of Greatbatch Medical).
- Susan M. Bratton: Appointed Executive Vice President for Business Development (previously President of Electrochem).
- Andrew Holman: Appointed Executive Vice President, Global Sales & Marketing.
- George Cintra: Appointed Senior Vice President and Chief Technology Officer.
Compensation for the promoted executives remains unchanged from their current arrangements.
Guidance, Outlook, and Risks
Management expects the realignment to optimize the Company's focus on profitable growth. The outlook includes incurring the aforementioned restructuring charges through the end of 2014, with the expectation of achieving annual savings of $7.0 million to $7.7 million once fully implemented. The filing does not explicitly list new risks or contingencies beyond the financial impact of the restructuring charges.
Investor Verification Checklist
- Verify the actual cash outflow timing for the $4.2 million to $5.0 million in restructuring charges.
- Monitor the realization of the projected $7.0 million to $7.7 million in annual savings.
- Review the attached press release (Exhibit 99.1) for further details on the strategic rationale.
- Confirm that the executive appointments do not trigger additional undisclosed compensation costs.